Mr Matthew Ellis
Matthew is a founding member of Robey Warshaw, a leading financial advisory firm. In recent years, Matthew has worked on some of the most high profile merger and acquisitions in the UK, including AstraZeneca / Pfizer and BG / Shell, and was listed by Financial News in their “40 under 40 rising stars” list in 2014. Before that, Matthew spent a number of years at Goldman Sachs and Merrill Lynch. Matthew joined the Board of Trustees in July 2016.
Dr Trevor Back
Trevor Back is a product manager at DeepMind where his role focuses on the translation of artificial intelligence to real-world problems in consumer, automotive, deep tech, and healthcare industries. Trevor was a founding member of DeepMind Health where he lead the research team to multiple Nature publications. Before DeepMind, he completed a Ph.D. in computational astrophysics at the University of Edinburgh.
Mr Jonathan Badger
Jonathan has worked in fundraising roles across the charity, Arts and higher education sectors over the last 33 years – for causes as varied as mental health, breast cancer and the environment to Cambridge University, where he was part of the small team that delivered Europe’s first billion-pound campaign. He is currently working as a fundraising consultant, supporting Arts and education clients alongside serving as Chief Executive of The Little Foundation.
Ms Marcella Turner
It was during Marcella’s experience of caring for her father, who had been diagnosed with prostate cancer, that Marcella realised the lack of culturally sensitive cancer support, together with the lack of awareness about cancer within the Black African, Black Caribbean and other culturally diverse communities. With over 14 years’ experience in the voluntary/charity sector, Marcella founded Can-Survive UK (CSUK). Based in Manchester, CSUK provides culturally sensitive support for people affected by cancer. Marcella is instrumental in the design, coordination and delivery of several cancer related campaigns working in partnership with mainstream cancer organisations and statutory health providers. She also sits on various cancer related Boards and committees. Marcella’s experience of losing her parents to cancer, drives her passion to address the cancer inequalities experienced by, and the lack of culturally appropriate cancer support services for Black African, Black Caribbean and other culturally diverse populations.
Mr Mark Clark
Mark is a consultant to the pharmaceutical industry. Previously, he spent 30 years in the City as an equity research analyst (most recently – until 2015- as joint head of Deutsche Bank’s highly-regarded European pharmaceutical research team). In addition to his consulting activities, Mark has volunteered for several health-related not-for-profit organisations and he is currently a Trustee of the international health NGO, Malaria Consortium.
Mr Richard Collier
Richard trained as a lawyer, was admitted to the bars of New York and the District of Columbia and practised law for 5 years. Following this he spent 23 years as an investment banker in London and New York specialising in mergers and acquisitions and was involved in some of the largest cross-border transactions of the period. He has been active as a trustee in the charity sector for the last 15 years. He was a Fellow and Chair of the Investment Committee of Balliol College, Oxford University. He also served as a non-executive director of OXIP, an investment fund managing assets for charities, university endowments and pension funds.
Sir Robert Francis QC
Sir Robert Francis QC is a barrister specialising in medical law and has been a Queen’s Counsel since 1992. He has chaired several healthcare related inquiries, including the Mid-Staffordshire NHS Foundation Trust Public Inquiry. He is a non-executive director of the Care Quality Commission, President of the Patients Association, and a Patron of the Florence Nightingale Foundation. He was knighted in 2014 for services to healthcare and patients.
Mr Ameet Gill OBE
Ameet advises a range of businesses and investors on UK and international politics, including helping them navigate complex policy problems. He is Founder of Hanbury Strategy, a strategic advisory firm that provides political analysis, develops communications strategies and uses cutting edge data and research to understand public opinion. Prior to founding Hanbury, he was Chief Speechwriter, Director of Strategic Communications and Director of Strategy to Prime Minister David Cameron. He has been described by the Mail on Sunday as ‘the most influential figure from an ethnic minority background in British politics’.
Mr Shaun Grady
Shaun Grady is Vice-President Business Development Operations at AstraZeneca. His career background includes roles at ICI, Zeneca, and AstraZeneca in Corporate, Pharmaceuticals and US Legal departments, HR and Business Development. Shaun has worked on major projects including the AstraZeneca merger, creation of Avecia and Syngenta, acquisition of Cambridge Antibody Technology (CAT), MedImmune and Amylin, and the spin out of Albireo.
Mrs Michele Hunter
Michele has been actively involved in the charity sector for nearly 30 years. She has been instrumental in raising over £10m for The October Club, she was Trustee of Children’s Liver Disease Foundation for 17 years and has managed high profile fundraising events for The Royal Hospital Chelsea, the Prostate Cancer Research Centre and others.
Mr Ben Monro-Davies
Ben Monro-Davies is a TV journalist currently working for Sky News. He has 20 years’ experience of news production. He launched All Out Politics with Adam Boulton, and was part of the launch team for Sky News at Ten. He also oversaw the 2012 relaunch of Channel 4 News, and oversaw special BBC1 programmes to mark the beginning and the conclusion of the EU referendum campaign. He has worked closely with many of the broadcasting world’s leading journalists.
Dr Suman Shirodkar
Dr. Suman Shirodkar, is a physician-scientist motivated by transformative science leading to significant patient benefit and commercially successful products. She has management consulting expertise, having led consulting engagements at McKinsey, and broad commercial experience in oncology, HIV and cardiovascular areas from previous roles at Pfizer and Novartis. She is now Chief Executive Officer at Cambridge Epigenetix Ltd. Suman has a Bachelor of Medicine & Bachelor of Surgery from the University of Bombay and competed a PhD in Virology at Harvard University.